SEARCH:   Advanced

Blood, 25 June 2009, Vol. 113, No. 26, pp. 6707-6715. Prepublished online as a Blood First Edition Paper on March 4, 2009; DOI 10.1182/blood-2008-09-178095. This Article Full Text (PDF) All Versions of this Article: blood-2008-09-178095v1 113/26/6707    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Robach, P. Articles by Cairo, G. Search for Related Content PubMed PubMed Citation Articles by Robach, P. Articles by Cairo, G. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 23, 2008 Accepted February 26, 2009 Alterations of systemic and muscle iron metabolism in human subjects treated with low dose recombinant erythropoietin Paul Robach, Stefania Recalcati, Domenico Girelli, Cecilia Gelfi, Niels J. Aachmann-Andersen, Jonas J. Thomsen, Anne M. Norgaard, Alessandra Alberghini, Natascia Campostrini, Annalisa Castagna, Agnese Vigano, Paolo Santambrogio, Tibor Kempf, Kai C. Wollert, Stephane Moutereau, Carsten Lundby, and Gaetano Cairo* Departement medical, Ecole Nationale de Ski et d'Alpinisme, Chamonix, France Department of Human Morphology and Biomedical Sciences "Citta Studi", University of Milano, Milano, Italy Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy Department of Sciences and Biomedical Technologies, University of Milano, Segrate, Italy The Copenhagen Muscle Research Centre, University of Copenhagen, Copenhagen, Denmark Protein Engineering Unit, Dibit, I.R.C.C.S., H.S. Raffaele, Milano, Italy Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany Laboratoire de Biochimie, Hopital Henri-Mondor, Creteil, France Department of Sport Science, University of Arhus, Arhus, Denmark * Corresponding author; email: gaetano.cairo{at}unimi.it. The high iron demand associated with enhanced erythropoiesis during high-altitude hypoxia leads to skeletal muscle iron mobilization and decrease in myoglobin protein levels (Blood 109:4724-31, 2007). In order to investigate the effect of enhanced erythropoiesis on systemic and muscle iron metabolism under non-hypoxic conditions, eight healthy volunteers were treated with recombinant erythropoietin (rhEpo) for one month. As expected, the treatment efficiently increased erythropoiesis and stimulated bone marrow iron use. It was also associated with a prompt and considerable decrease in urinary hepcidin, and a slight transient increase in GDF-15. The increased iron use and reduced hepcidin levels suggested increased iron mobilization, but the treatment was associated with increased muscle iron and L ferritin levels. The muscle expression of transferrin receptor and ferroportin was up-regulated by rhEpo administration, whereas there was no appreciable change in myoglobin levels, which suggests unaltered muscle oxygen homeostasis. In conclusion, under rhEpo stimulation, the changes in the expression of muscle iron proteins indicate the occurrence of skeletal muscle iron accumulation despite the remarkable hepcidin suppression that may be mediated by several factors, such as rhEpo and/or decreased transferrin saturation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Muscle iron in stress erythropoiesis? Marc Kerenyi and Ernst W. Müllner Blood 2009 113: 6507-6508. [Full Text] [PDF] This article has been cited by other articles: M. Kerenyi and E. W. Mullner Muscle iron in stress erythropoiesis? Blood, June 25, 2009; 113(26): 6507 - 6508. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020